Immunexpress Appoints Dr. Roy Davis Chief Medical Officer

SEATTLE, Oct. 22, 2015 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the appointment of Roy F. J. Davis, Ph.D., M.D., M.H.A., as Chief Medical Officer.

"Dr. Davis has over 30 years of experience providing and directing patient care for multiple healthcare-provider organizations," said Roslyn Brandon, President and CEO of Immunexpress. "His wealth of knowledge in the implementation of the sepsis surveillance programs will prove extraordinarily useful as we advance our molecular diagnostic test for sepsis toward clearance by the FDA."

Dr. Davis previously served from 2002 through 2013 as Chief Medical Officer of Providence Health and Services' Alaska region where he assisted in the implementation of the modified early warning system (MEWS) and sepsis surveillance algorithms using the Microsoft Amalga platform. Dr. Davis was named the Microsoft Investigator of the Year for his work with MEWS in 2012. From 1986 to 1998, he was a Clinical Assistant Professor with the WAMI program in the Department of Pediatrics at the University of Washington.

Dr. Davis holds a medical degree and a clinical chemistry from the Medical College of Virginia and completed his internship and residency in pediatrics at the University of Washington Children's Hospital. Dr. Davis also holds an M.H.A. from the University of Colorado School of Business.

About Immunexpress

Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Immunexpress's SeptiCyte® technology quantifies directly from whole blood specific molecular markers from the patient's own immune system the "host response." Detecting the host's septic immune response can diagnose sepsis earlier and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen. Immunexpress's pipeline includes monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer platforms. For more information visit

Follow Immunexpress on Twitter at and LinkedIn at

Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4262
[email protected]
[email protected]

To view the original version on PR Newswire, visit:

SOURCE Immunexpress, Inc.

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.